Medicine

Adverum Biotechnologies attends the Jefferies Cell and Genetic Medicine Summit

Adverum Biotechnologies attends the Jefferies Cell and Genetic Medicine Summit
ADVERTISEMENT

Adverum Biotechnologies, Inc.

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company looking to establish gene therapy as a new standard of care for common eye diseases, today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29. Sept. 2022 at 9:30 a.m. ET.

The on-demand webcast corporate presentation is accessible under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for 90 days after the presentation.

About Adverum Biotechnology

ADVERTISEMENT

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company committed to establishing gene therapy as a new standard of care for common eye diseases with the goal of developing functional treatments to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing sustainable single-dose therapies designed to be administered in physician’s offices to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogenic soroparvovec (Ixo-vec, formerly ADVM-022), as a one-time IVT injection for patients with neovascular or wet age-related macular degeneration. By addressing the challenges associated with current treatment paradigms for these debilitating eye diseases, Adverum strives to transform the standard of care, preserve vision and create a profound societal impact around the world. For more information, visit www.adverum.com.

Business and Investor Questions

Anand Reddic
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
E: areddi@adverum.com

Media

Megan Talon
Associate Director, Corporate Communications
Adverum Biotechnologies, Inc.
T: 650-649-1006
E: mtalon@adverum.com

ADVERTISEMENT1

Leave a Comment